US EditionPublished • loading... • Updated
Samsung Biologics to buy US drug production facility from GSK for $280 million
Samsung Biologics secures its first U.S. manufacturing site with a 60,000-liter capacity plant in Rockville, Maryland, aiming to reduce supply-chain risks and meet rising U.S. demand.
- On December 21, 2025, Samsung Biologics America signed a definitive agreement to acquire 100% of Human Genome Sciences' Rockville plant for $280 million, with John Rim saying it's a "landmark acquisition".
- Facing U.S. tariff exposure, Samsung Biologics pursued a U.S. manufacturing foothold to provide flexible multi-site options across the U.S. and Korea, citing prior reliance on Korean plants and GSK's $30bn investment commitment.
- The Rockville site houses two cGMP plants with a combined 60,000 liters of drug substance capacity, Samsung Biologics will retain more than 500 employees, and the takeover included the existing order backlog.
- Closing is scheduled within the first quarter of next year, and Samsung on Monday announced three contract manufacturing organization contracts with European pharmaceutical companies worth a combined 1.22 trillion won.
- With 785,000 liters across five plants in Incheon, Samsung Biologics anchors a large global capacity network and applies its ExellenS framework, recently completing Bio Campus I and II and securing land for Bio Campus III.
Insights by Ground AI
55 Articles
55 Articles
The Daily Advance+38 Reposted by 38 other sources
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply networkAdditional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programsUnderscores Samsung Biologics' long-term dedication to…
Coverage Details
Total News Sources55
Leaning Left3Leaning Right5Center15Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
13%
C 65%
R 22%
Factuality
To view factuality data please Upgrade to Premium
